SOURCE-LINKED STUDY SUMMARY
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Abstract summarizedQuality not appraised
- What was studied
- This randomized trial tested whether the oral GH secretagogue MK-677 changed GH secretion, body composition, and energy expenditure.
- Who / model studied
- Twenty-four otherwise healthy men with obesity, aged 18–50, had BMI above 30 kg/m² and waist-to-hip ratio above 0.95.
- Studied dose & schedule
- Twelve men received oral MK-677 25 mg daily and 12 received placebo for 8 weeks.
- What the study found
- IGF-I rose about 40%. Fat-free mass increased, but total and visceral fat did not. Basal metabolic rate rose at week 2 but not week 8, while oral glucose tolerance showed impaired glucose homeostasis.
- Limitations & context
- The trial was short and small, reported fat-free mass rather than direct muscle imaging, and did not demonstrate reduced body fat.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1210/jcem.83.2.4539